During the 2023-2024 winter season, a new preventive treatment, nirsevimab (Beyfortus®), was offered to parents leaving the maternity ward in order to protect newborns from the most serious forms of the disease and thus avoid hospitalization. This treatment has had a very high adherence rate.
In the Paca region, between September and the end of December 2023, more than 9,800 infants have received this treatment leaving the maternity ward, i.e. more than 72% of newborns over this period.
According to Santé Publique France, this first campaign confirmed the effectiveness of nirsevimab (Beyfortus®), with a reduction in immunized infants of almost 80% in the risk of developing a serious form of bronchiolitis requiring hospitalization in intensive care.
At the national level, it made it possible to avoid 5,800 hospitalizations for RSV bronchiolitis after going to the emergency room1.
A new preventive treatment campaign with Beyfortus® is being relaunched this year for infants under one year old. The treatment will be available this year after leaving maternity wards and in town pharmacies.
Health
Related News :